ersodetug
·Code: RZ358
ersodetug: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Rezolute, Inc. (RZLT) | Phase 3 |
Clinical Trials (1)
A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)
FDA Decisions
FDA_MeetingThe Company announced alignment with the FDA on the design for the ongoing Phase 3 trial of Ersodetug in Tumor Hyperinsulinism.(RZLT)
Frequently asked questions
Who is developing ersodetug?
ersodetug is being developed by Rezolute, Inc..
How many clinical trials involve ersodetug?
BioSniper tracks 1 clinical trial involving ersodetug.
What is ersodetug's latest FDA decision?
The most recent tracked FDA decision for ersodetug is FDA_Meeting for The Company announced alignment with the FDA on the design for the ongoing Phase 3 trial of Ersodetug in Tumor Hyperinsulinism., dated September 2, 2025.
Get deeper analysis on ersodetug
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis